Safety Tolerability Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

  • STATUS
    Recruiting
  • participants needed
    160
  • sponsor
    Enyo Pharma
Updated on 4 August 2021
Investigator
Couchoux Harold
Primary Contact
ENYO PHARMA Investigative site 0207 (2.3 mi away) Contact
+40 other location
fibrosis

Summary

The purpose of this study is to assess the effects of EYP001a with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in patients with NASH

Details
Condition Non Alcoholic Steatohepatitis
Treatment Placebo, EYP001a
Clinical Study IdentifierNCT03812029
SponsorEnyo Pharma
Last Modified on4 August 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note